Ibandronate: Efficacy in the treatment of metastatic bone disease

Future Oncology

Volumn 1, Issue 5, 2005, Pages 593-607

  Diel, Ingo J ^a  

^a CGG Klinik GmbH   (Germany)

Author keywords

biophosphonate; cancer; pain; renal safety; skeletal event

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IBANDRONIC ACID;

BONE TUMOR; CLINICAL TRIAL; HUMAN; METASTASIS; OSTEOLYSIS; REVIEW;

BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BONE RESORPTION; CLINICAL TRIALS; DIPHOSPHONATES; HUMANS;

EID: 33747606828     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.1.5.593     Document Type: Article

References (69)

1. Van Poznak CH: The use of bisphosphonates in patients with breast cancer. Cancer Control 9, 480-489 (2002
2. Coleman RE: Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat. Rev. 27, 165-176 (2001
3. Mundy GR: Metastasis to bone: causes, consequences and therapeutic opportunities. Nature Rev. Cancer 2, 584-593 (2002
4. Roodman GD: Mechanisms of bone metastasis. N. Engl. J. Med. 350, 1655-1664 (2004
5. Conte P, Coleman R: Bisphosphonates in the treatment of skeletal metastases. Semin. Oncol. 31, 59-63 (2004
6. Coleman RE: Bisphosphonates: clinical experience. Oncologist 9(Suppl. 4), 14-27 (2004
7. Ross JR, Saunders Y, Edmonds PM et al.: Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. BR. MED. J. 327, 469 (2003
8. Wong R, Wiffen PJ: Bisphosphonates for the relief of pain secondary to bone metastases. Cochrane Database Syst. Rev. Art. No. CD002068 (2002
9. Costa L, Demers LM, Gouveia-Oliveira A et al.: Prospective evaluation of the peptidebound collagen Type I cross-links Ntelopeptide and C-telopeptide in predicting bone metastases status. J. Clin. Oncol. 20, 850-856 (2002
10. Brown JE, Cook RJ, Major P et al.: Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J. Natl Cancer Inst. 97, 59-69 (2005
11. Coleman RE: Bisphosphonates in breast cancer. Ann. Oncol. 15, 687-695 (2005
12. Rosen LS, Gordon D, Kaminski M et al.: Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a Phase III, doubleblind, comparative trial. Cancer J. 7, 377-387 (2001
13. Rosen LS, Gordon D, Kaminski M et al.: Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, doubleblind, multicenter, comparative trial. Cancer 98, 1735-1744 (2003
14. Rosen LS, Gordon DH, Dugan W, Jr. et al.: Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 100, 36-43 (2004
15. Conte P,Guarneri V: Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. Oncologist 9(Suppl. 4), 28-37 (2004
16. Body JJ, Diel I,Bell R: Profiling the safety and tolerability of bisphosphonates. Semin. Oncol. 31, 73-78 (2004
17. Robertson AG, Reed NS,Ralston SH: Effect of oral clodronate on metastatic bone pain: a double-blind, placebo-controlled study. J. Clin. Oncol. 13, 2427-2430 (1995
18. Paterson AH, Powles TJ, Kanis JA et al.: Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J. Clin. Oncol. 11, 59-65 (1993
19. Powles T, Paterson S, Kanis JA et al.: Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J. Clin. Oncol. 20, 3219-3224 (2002
20. Atula S, Powles T, Paterson A et al.: Extended safety profile of oral clodronate after long-term use in primary breast cancer patients. Drug Saf. 26, 661-671 (2003
21. Rosen LS, Gordon D, Tchekmedyian NS et al.: Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer 100, 2613-2621 (2004
22. Russell RG, Croucher PI,Rogers MJ: Bisphosphonates: pharmacology, mechanisms of action and clinical uses. Osteoporos. Int. 9 (Suppl. 2), S66-80 (1999
23. Rogers MJ, Gordon S, Benford HL et al.: Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88, 2961-2978 (2000
24. Barrett J, Worth E, Bauss F,Epstein S: Ibandronate: a clinical pharmacological and pharmacokinetic update. J. Clin. Pharmacol. 44, 951-965 (2004
25. Leyland-Jones B: Pharmacokinetic and clinical equivalence of oral and intravenous ibandronate for metastatic bone disease. Eur. J. Cancer 2(Suppl.), 9-12 (2004
26. Bauss F, Endele R, Besenfelder E, Hoelck JP: Ibandronate: serum kinetics, tissue distribution and binding to bone following intravenous bolus injection (Abstract P-128). Calcif. Tissue Int. 70, 289-290 (2002
27. Pecherstorfer M, Ludwig H, Schlosser K et al.: Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous bolus injection. J. Bone Miner. Res. 11, 587-593 (1996
28. Schlosser K, Scigalla P: Biochemical markers as surrogates in clinical trials in patients with metastatic bone disease and osteoporosis. Scand. J. Clin. Lab. Invest. 57 (Suppl. 227), 21-28 (1997
29. Coleman RE, Purohit OP, Black C et al.: Double-blind, randomised, placebocontrolled, dose-finding study of oral ibandronate in patients with metastatic bone disease. Ann. Oncol. 10, 311-316 (1999
30. Body JJ, Diel IJ, Lichinitser MR et al.: Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases (Corrigendum published in Ann. Oncol. 15, 180 [2004]). Ann. Oncol. 14, 1399-1405 (2003
31. Diel IJ, Body JJ, Lichinitser MR et al.: Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. Eur. J. Cancer 40, 1704-1712 (2004
32. Tripathy D, Budde M: Assessing the efficacy of ibandronate for the prevention of skeletal-related events (SREs) in metastatic bone disease: a methodological comparison. Bone 34, S46-S99 (2004
33. Body JJ, Diel IJ, Bell R et al.: Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain 111, 306-312 (2004
34. Body JJ, Diel IJ, Lichinitzer M et al.: Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled Phase III studies. Br. J. Cancer 90, 1133-1137 (2004
35. Heras P, Karagiannis S, Kritikos K et al.: Ibandronate is effective in preventing skeletal events in patients with bone metastases secondary to breast and colorectal cancer (Abstract 853P). Ann. Oncol. 15(Suppl. 3), iii225 (2004
36. Heras P, Karagiannis S, Kritikos K et al.: Ibandronate is effective in preventing skeletal events in patients with bone metastases secondary to colorectal carcinoma (Abstract 3639). J. Clin. Oncol. 23(Suppl.), 280s (2005
37. Terpos E, Viniou N, de la Fuente J et al.: Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myeloma. Eur. J. Haematol. 70, 34-42 (2003
38. Body JJ: Is ibandronate effective in multiple myeloma? (letter). Eur. J. Haematol. 71, 470-472 (2003
39. Mancini I, Dumon JC,Body JJ: Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease: a pilot study. J. Clin. Oncol. 22, 3587-3592 (2004
40. Heidenreich A, Elert A,Hofmann R: Ibandronate in the treatment of prostate cancer associated painful osseous metastases. Prostate Cancer Prostatic Dis. 5, 231-235 (2002
41. Ohlmann C, Heidenreich A: Efficacy of ibandronate in the management of painful osseous metastases due to hormone refractory prostate cancer (Abstract A-38). Support. Care Cancer 11, 396 (2003
42. Heidenreich A, Ohlmann C, Olbert P,Hegele A: High-dose ibandronate is effective and well-tolerated in the treatment of pain and hypercalcaemia due to metastatic urologic cancer. Eur. J. Cancer. (Suppl. 1), S270 (2003
43. Pecherstorfer M,Diel IJ: Rapid administration of ibandronate does not affect renal functioning: evidence from clinical studies in metastatic bone disease and hypercalcaemia of malignancy. Support. Care Cancer 12, 877-881 (2004
44. Lyubimova NV, Kushlinsky NE, Lichinitser MR,Schlosser K: Renal safety of intravenous ibandronic acid in breast cancer patients with metastatic bone disease. Clin. Drug Invest. 23, 707-716 (2003
45. Pecherstorfer M, Diel IJ,Bergstrom B: Longterm (4-year) safety of intravenous ibandronate in metastatic breast cancer: an open label study (Abstract 255). Eur. J. Cancer. Suppl. 2, 130 (2004
46. Bell R, Body JJ,Bergstrom B: Renal safety of intravenous ibandronate for up to 4 years in patients with breast cancer and bone metastases. San Antonio Breast Cancer Symposium, San Antonio, USA (2004
47. Syrigos KN, Michalaki V, Mitromaras A et al.: Safety and efficacy of the new bisphosphonate ibandronate in the management of bone metastasis following rapid infusion. In vivo 16, 361-363 (2002
48. Heidenreich A, Ohlmann C,Bergner R: Renal safety of loading dose ibandronate in urological patients with compensated renal insufficiency (Abstract 95). Cancer Treat. Rev. 31 (Suppl. 1), S5 0-51 (2005
49. Bergner R, Henrich DM, Hoffmann M et al.: Renal safety of ibandronate in multiple myeloma patients with renal deterioration. Focus on Myeloma and Plasma Cell Disorders, Las Vegas, USA (2005
50. Tripathy D, Lichinitzer M, Lazarev A et al.: Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial. Ann. Oncol. 15, 743-750 (2004
51. Cameron D, Murray R, Tripathy D,Bergstrom B: Long-term safety of oral ibandronate in patients with skeletal metastases from breast cancer: 4-year followup data (Abstract 275). Eur. J. Cancer Suppl. 2, 136 (2004
52. Lipton A: Toward new horizons: the future of bisphosphonate therapy. Oncologist 9 (Suppl. 4), 38-47 (2004
53. Wittrant Y, Theoleyre S, Chipoy C et al.: RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. Biochim. Biophys. Acta 1704, 49-57 (2004
54. Heymann D, Fortun Y, Redini F,Padrines M: Osteolytic bone diseases: physiological analogues of bone resorption effectors as alternative therapeutic tools. Drug Discov. Today 10, 242-247 (2005
55. Fromigue O, Lagneaux L,Body JJ: Bisphosphonates induce breast cancer cell death in vitro. J. Bone Miner. Res. 15, 2211-2221 (2000
56. Hiraga T, Williams PJ, Mundy GR,Yoneda T: The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. Cancer Res. 61, 4418-4424 (2001
57. Vorotnjak M, Boos J,Lanvers-Kaminsky C: In vitro toxicity of bisphosphonates on human neuroblastoma cell lines. AntiCancer Drugs 15, 795-802 (2004
58. van der Pluijm G, Vloedgraven H, van Beek E et al.: Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J. Clin. Invest. 98, 698-705 (1996
59. Boissier S, Magnetto S, Frappart L et al.: Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res. 57, 3890-3894 (1997
60. Boissier S, Ferreras M, Peyruchaud O et al.: Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res. 60, 2949-2954 (2000
61. Magnetto S, Boissier S, Delmas PD,Clezardin P: Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone. Int. J. Cancer 83, 263-269 (1999
62. Crohns CA, Untch M, Konecny G: Different bisphosphonates have direct cytotoxic effects on three breast cancer cell lines and fresh breast cancer tumor tissue (Abstract 2005). Proc. Am. Soc. Clin. Oncol. (2001
63. Vogt U, Bielawski KP, Bosse U,Schlotter CM: Breast tumour growth inhibition in vitro through the combination of cyclophosphamide/metotrexate/5- fluorouracil, epirubicin/cyclophosphamide, epirubicin/paclitaxel, and epirubicin/docetaxel with the bisphosphonates ibandronate and zoledronic acid. Oncol. Rep. 12, 1109-1114 (2004
64. Jaschke A, Bastert G, Solomayer EF et al.: Adjuvant clodronate treatment improves the overall survival of primary breast cancer patients with micrometastases to bone marrow - a longtime follow-up (Abstract 529). J. Clin. Oncol. 22 (Suppl. 14S), 9 (2004
65. Powles T, McCloskey E,Kurkilahti M: Oral clodronate for adjuvant treatment of operable breast cancer: results of a randomized, double-blind, placebocontrolled multicenter trial (Abstract 528). J. Clin. Oncol. 22 (Suppl. 14S), 8 (2004
66. Saarto T, Vehmanen L, Virkkunen P,Blomqvist C: Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol. 43, 650-656 (2004
67. Heidenreich A,Ohlmann CH: Ibandronate: its pharmacology and clinical efficacy in the management of tumor-induced hypercalcemia and metastatic bone disease. Expert Rev. Anticancer Ther. 4, 991-1005 (2004
68. Body JJ, Lichinitser MR, Andreeva N, Budde M,Bergstrom B: Safety of an intravenous (i.v.) dose of ibandronate followed by daily oral dosing in metastatic bone disease: results of an open-label study (Abstract 735). J. Clin. Oncol. 22 (Suppl. 14S), 60 (2004
69. Menssen HD, Sakalova A, Fontana A et al.: Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma. J. Clin. Oncol. 20, 2353-2359 (2002